Cantor Fitzgerald Reiterates Overweight on LifeMD, Maintains $15 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Sarah James has reiterated an Overweight rating on LifeMD (NASDAQ:LFMD) and maintained a $15 price target.
August 09, 2024 | 3:34 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald analyst Sarah James has reiterated an Overweight rating on LifeMD and maintained a $15 price target.
The reiteration of an Overweight rating and a maintained price target of $15 by a reputable analyst is likely to positively impact LifeMD's stock price in the short term as it signals confidence in the company's performance and potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100